Objective  Comparing the clinical efficacy of moxifloxacin and azithromycin in the treatment of Mycoplasmal pneumoniae pneumonia (MPP).

Methods  MPP patients admitted to our hospital from January 2023 to May 2024 were selected and randomly divided into the observation group and the control group. Both groups were given conventional treatment such as salbutamol and budesonide aerosol inhalation. Additionally, the control group was given azithromycin 0.5 g, ivd, qd, and the observation group was given moxifloxacin 0.4 g, ivd, qd. After one week of treatment, the efficacy, symptom disappearance time and adverse drug reactions occurrence of the two groups were compared. The serum inflammatory markers [white blood cell count (WBC), interleukin-6 (IL-6), C-reactive protein (CRP), procalcitonin (PCT)], immunoglobulin indicators (IgA, IgG, IgM), T lymphocyte subset indicators (CD3⁺, CD4⁺, and CD4⁺/CD8⁺) before and after treatment were compared between the two groups.

Results  A total of 80 patients were included and each group was 40 patients. After treatment, the total effective rate of observation group (95.00%) was higher than that of control group (75.00%) (P<0.05). The disappearance time of symptoms (cough, fever, and lung rales) in the observation group was significantly lower than that in the control group (P<0.05). After treatment, the levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in both groups significantly increased, while the levels of serum IL-6, CRP, PCT, WBC, IgA, IgM, and IgG significantly decreased (P<0.05), with the observation group showing better results (P<0.05). There was no significantiy difference in the incidence of adverse reactions between the two groups (P>0.05).

Conclusion  Moxifloxacin is more effective than azithromycin in the treatment of MPP, which can relieve symptoms, improve immune function, reduce inflammatory response, and has a relatively good safety profile.

1.明建军, 杨巧玲, 孙华君, 等. 环丙沙星治疗儿童耐大环内酯类支原体肺炎的回顾性分析[J]. 药物流行病学杂志, 2022, 31(12): 803-807. [Ming JJ, Yang QL, Sun HJ, et al. Retrospective analysis of ciprofloxacin for the treatment of macrolide-resistant Mycoplasma pneumonia in children[J]. Chinese Journal of Pharmacoepidemiology, 2022, 31(12): 803-807.] DOI: 10.19960/j.cnki. issn1005-0698. 2022.12.004.

2.Davis J, Ericson JE, Kavanagh R. Severe pediatric Mycoplasma pneumoniae infection requiring veno-venous extracorporeal membrane oxygenation[J]. Pediatr Infect Dis J, 2021, 40(4): e154-e156. DOI: 10.1097/INF.0000000000003051.

3.李心雨, 杨延斌. 肺炎支原体肺炎的治疗进展[J]. 临床医学进展, 2024, 14(12): 490-495. [Li XY, Yang YB. Progress in the treatment of Mycoplasma pneumoniae pneumonia[J]. Progress in Clinical Medicine, 2024, 114(12): 490-495.] DOI: 10.12677/acm.2024. 14123108.

4.王宏杰. 莫西沙星与阿奇霉素治疗成人支原体肺炎的临床有效性研究[J]. 世界复合医学, 2022, 8(8): 183-186, 191. [Wang HJ. Clinical efficacy of moxifloxacin and azithromycin in the treatment of adult Mycoplasma pneumoniae pneumonia[J]. World Journal of Integrative Medicine, 2020, 8(8): 183-186, 191.] DOI: 10.11966/j.issn.2095-994X.2022.08.08.46.

5.唐成, 刘和平. 莫西沙星与阿奇霉素治疗成人支原体肺炎的临床效果比较[J]. 临床合理用药杂志, 2021, 14(19): 79-81. [Tang C, Liu HP. Comparison of the clinical effects of moxifloxacin and azithromycin in the treatment of Mycoplasma pneumonia in adults[J]. Journal of Clinical Rational Drug Use, 2021, 14(19): 79-81.] DOI: 10.15887/j.cnki.13-1389/r.2021.19.029.

6.陈建东, 黄立, 陈凯, 等. 莫西沙星注射液联合吸入性乙酰半胱氨酸治疗重症肺炎患者的临床研究[J]. 中国临床药理学杂志, 2023, 39(7): 920-923. [Chen JD, Huang L, Chen K, et al. Clinical study of moxifloxacin injection combined with inhaled acetylcysteine in the treatment of patients with severe pneumonia[J]. Chinese Journal of Clinical Pharmacology, 2023, 39(7): 920-923.] DOI: 10.13699/j.cnki.1001-6821.2023.07.002.

7.中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南（2016年版）[J]. 中华结核和呼吸杂志, 2016, 39(4): 253-279. [Chinese Medical Association Respiratory Disease Branch. Guidelines for the diagnosis and treatment of community-acquired pneumonia in Chinese adults (2016 edition) [J]. Chinese Journal of Tuberculosis and Respiratory, 2016, 39(4): 253-279.] DOI: 10.3760/cma.j.issn.1001-0939.2016.04.005.

8.Lee KL, Lee CM, Yang TL, et al. Severe Mycoplasma pneumoniae pneumonia requiring intensive care in children, 2010-2019[J]. J Formos Med Assoc, 2021, 120(1 Pt1): 281-291. DOI: 10.1016/j.jfma.2020.08.018.

9.朱雷. 观察阿奇霉素序贯疗法用于小儿肺炎支原体肺炎（MPP）临床治疗的效果—评《小儿呼吸系统疾病诊疗与护理》 [J]. 中国辐射卫生, 2022, 31(2): 259. [Zhu L. Observation of the effect of azithromycin sequential therapy for the clinical treatment of pediatric Mycoplasma pneumoniae pneumonia (MPP)-a review of Pediatric Respiratory Disease Diagnosis, Treatment and Care[J]. China Radiation Health, 2022, 31(2): 259.] https://d.wanfangdata.com.cn/periodical/Ch9QZXJpb2RpY2FsQ0hJTmV3UzIwMjUwMTE2MTYzNjE0Eg96Z2Zzd3MyMDIyMDIwMjQaCDY0czJxbzR6.

10.薄红晓. 盐酸氨溴索联合阿奇霉素序贯疗法对支原体肺炎患儿免疫功能及心肌酶谱的影响[J]. 山西医药杂志, 2020, 49(4): 440-442. [Bo HX. Effect of sequential therapy of ambroxol hydrochloride combined with azithromycin on immune function and cardiac enzyme spectrum of children with Mycoplasma pneumonia[J]. Shanxi Medical Journal, 2020, 49(4): 440-442.] DOI: 10.3969/j.issn.0253-9926.2020.04.030.

11.刘孔华. 阿奇霉素联合布地奈德雾化吸入治疗小儿支原体肺炎的疗效观察[J]. 中国现代药物应用, 2020, 14(10): 125-126. [Liu KH. Observation on the efficacy of azithromycin combined with budesonide nebulized inhalation in the treatment of pediatric Mycoplasma pneumonia[J]. China Modern Drug Application, 2020, 14(10): 125-126.] DOI: 10.14164/j.cnki.cn11-5581/r.2020. 10.058.

12.杨梅, 王晓玲, 钱素云. 莫西沙星治疗儿童重症肺炎支原体肺炎的安全性和有效性分析[J]. 中华急诊医学杂志, 2021, 30(8): 982-986. [Yang M, Wang XL, Qian SY. Safety and efficacy analysis of moxifloxacin in the treatment of severe Mycoplasma pneumoniae pneumonia in children[J]. Chinese Journal of Emergency Medicine, 2021, 30(8): 982-986.] DOI: 10.3760/cma. j.issn.1671-0282.2021.08.013.

13.张琳琳, 陈蕾, 李春红, 等. 莫西沙星与左氧氟沙星治疗老年社区获得性肺炎患者的效果对比[J]. 中国药物滥用防治杂志, 2022, 28(7): 941-945. [Zhang LL, Chen L, Li CH, et al. Comparison of moxifloxacin and levofloxacin in the treatment of elderly patients with community-acquired pneumonia[J]. Chinese Journal of Drug Abuse Prevention and Treatment, 2022, 28(7): 941-945.] DOI: 10.15900/j.cnki.zylf1995.2022.07.031.

14.何礼贤. 学习和实践《社区获得性肺炎诊断和治疗指南》 [J]. 中华结核和呼吸杂志, 2006, 29(10): 649-650. [He LX. Learning and practicing the Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia[J]. Chinese Journal of Tuberculosis and Respiratory Medicine, 2006, 29(10): 649-650.] DOI: 10.3760/j:issn:1001-0939.2006.10.001.

15.王超, 陈晓君, 宋晓莉, 等. 莫西沙星左氧氟沙星序贯给药对老年重症慢性阻塞性肺疾病急性加重期患者呼吸功能微炎症的影响研究[J]. 河北医学, 2023, 29(4): 685-689. [Wang C, Chen XJ, Song XL, et al. Study on the effect of moxifloxacin levofloxacin sequential administration on respiratory function microinflammation in elderly patients with severe acute exacerbation of chronic obstructive pulmonary disease[J]. Hebei Medicine, 2023, 29(4): 685-689.] DOI: 10.3969/j.issn.1006-6233.2023.04.032.

16.李革, 余怡如, 陈放, 等. NLR、25-(OH)D3、IL-6、PCT与重症肺炎支原体肺炎患儿免疫功能和预后不良的关系研究 [J]. 现代生物医学进展, 2023, 23(3): 461-465, 528. [Li G, Yu YR, Chen F, et al. Relationship of NLR, 25-(OH)D3, IL-6, PCT with immune function and poor prognosis in children with severe Mycoplasma pneumoniae pneumonia[J]. Advances in Modern Biomedicine, 2023, 23(3): 461-465, 528.] DOI: 10.13241/j.cnki.pmb.2023.03.012.

17.喻承伟, 何芳志, 贺燕, 等. 血必净注射液联合莫西沙星序贯给药治疗老年重症社区获得性肺炎的效果及对外周血T淋巴细胞亚群和TNF-α、IL-6水平的影响[J]. 中国医学创新, 2022, 19(35): 134-139. [Yu CW, He FZ, He Y, et al. Effect of hemopexin injection combined with moxifloxacin sequential administration in the treatment of severe community-acquired pneumonia in the elderly and its effect on peripheral blood T-lymphocyte subpopulations and levels of TNF-α and IL-6[J]. China Medical Innovation, 2022, 19(35): 134-139.] DOI: 10.3969/j.issn.1674-4985.2022.35.032.

18.王晓, 贺红安, 张葆青. 基于网络药理学和分子对接探讨甘露消毒丹治疗肺炎支原体肺炎的机制[J]. 中国现代应用药学, 2022, 39(3): 343-351. [Wang X, He HA, Zhang BQ. Exploring the mechanism of Ganlu Sterilizing Dan in the treatment of Mycoplasma pneumoniae pneumonia based on network pharmacology and molecular docking[J]. China Modern Applied Pharmacy, 2022, 39(3): 343-351.] DOI: 10.13748/j.cnki.issn1007-7693.2022.03.010.

19.庞卫花, 李金巍, 宗广帅, 等. 阿奇霉素联合布地奈德对支原体肺炎患儿细胞因子、共刺激分子和免疫功能的影响[J]. 河北医药, 2020, 42(3): 362-365. [Pang WH, Li JW, Zong GS, et al. Effects of azithromycin combined with budesonide on cytokines, co-stimulatory molecules and immune function in children with Mycoplasma pneumonia[J]. Hebei Medicine, 2020, 42(3): 362-365.] DOI: 10.3969/j.issn.1002-7386.2020.03.009.